An informatic pipeline for managing high-throughput screening experiments and analyzing data from stereochemically diverse libraries
暂无分享,去创建一个
Paul A. Clemons | Willmen Youngsaye | Dennis Moccia | David L. Lahr | Philip Montgomery | Jacob K. Asiedu | Steve Brudz | Joshua A. Bittker | Sivaraman Dandapani | Nicola J. Tolliday | Lakshmi B. Akella | Andrea de Souza | Carol A. Mulrooney | Michael J. Quintin | Evan L. Mulligan | Lisa A. Marcaurelle | Jeremy R. Duvall | P. Clemons | D. L. Lahr | Philip Montgomery | N. Tolliday | Sivaraman Dandapani | E. Mulligan | Willmen Youngsaye | D. Moccia | D. Lahr | L. Akella | L. Marcaurelle | S. Brudz | Michael J. Quintin
[1] Nathan T. Ross,et al. An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors. , 2010, Journal of the American Chemical Society.
[2] Paul A Clemons,et al. Relationship of stereochemical and skeletal diversity of small molecules to cellular measurement space. , 2004, Journal of the American Chemical Society.
[3] Jason T. Lowe,et al. Synthesis of a 35-member stereoisomer library of bistramide A: evaluation of effects on actin state, cell cycle and tumor cell growth. , 2009, The Journal of organic chemistry.
[4] Patrick W. Faloon,et al. Synthesis of a novel suppressor of beta-cell apoptosis via diversity-oriented synthesis. , 2011, ACS medicinal chemistry letters.
[5] Sanjay Joshua Swamidass,et al. Utility-Aware Screening with Clique-Oriented Prioritization , 2012, J. Chem. Inf. Model..
[6] J. Reynisson,et al. Bond stability of the "undesirable" heteroatom-heteroatom molecular moieties for high-throughput screening libraries. , 2011, European journal of medicinal chemistry.
[7] N. Meanwell. Synopsis of some recent tactical application of bioisosteres in drug design. , 2011, Journal of medicinal chemistry.
[8] C. Richard,et al. Fluorous mixture synthesis of stereoisomer libraries: total syntheses of (+)-murisolin and fifteen diastereoisomers. , 2004, Journal of the American Chemical Society.
[9] Andreas Sewing,et al. Evaluating Real-Life High-Throughput Screening Data , 2005, Journal of biomolecular screening.
[10] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[11] S Joshua Swamidass,et al. An Economic Framework to Prioritize Confirmatory Tests after a High-Throughput Screen , 2010, Journal of biomolecular screening.
[12] Martin Serrano,et al. Nucleic Acids Research Advance Access published October 18, 2007 ChemBank: a small-molecule screening and , 2007 .
[13] Jeremy R. Duvall,et al. Synthesis of a stereochemically diverse library of medium-sized lactams and sultams via S(N)Ar cycloetherification. , 2011, ACS combinatorial science.
[14] Sanjay Joshua Swamidass,et al. Enhancing the rate of scaffold discovery with diversity-oriented prioritization , 2011, Bioinform..
[15] P. Verhoest,et al. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.
[16] C. Wilcox,et al. Total synthesis of a 28-member stereoisomer library of murisolins. , 2006, Journal of the American Chemical Society.
[17] Paul A. Clemons,et al. Using biological performance similarity to inform disaccharide library design. , 2009, Journal of the American Chemical Society.
[18] Nathalie Meurice,et al. Softening the Rule of Five--where to draw the line? , 2012, Bioorganic & medicinal chemistry.
[19] Gavin Harper,et al. Methods for mining HTS data. , 2006, Drug discovery today.
[20] D. Curran,et al. Synthesis of all 16 stereoisomers of pinesaw fly sex pheromones--tools and tactics for solving problems in fluorous mixture synthesis. , 2005, The Journal of organic chemistry.
[21] C. Humblet,et al. Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.
[22] Stuart L. Schreiber,et al. Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections , 2011, Proceedings of the National Academy of Sciences.
[23] Lorenz M Mayr,et al. The Future of High-Throughput Screening , 2008, Journal of biomolecular screening.
[24] Ernesto Callegari,et al. A comprehensive listing of bioactivation pathways of organic functional groups. , 2005, Current drug metabolism.
[25] Mathias Wawer,et al. Extraction of structure-activity relationship information from high-throughput screening data. , 2009, Current medicinal chemistry.
[26] G. V. Paolini,et al. Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.
[27] Xiang Yao,et al. Advanced Biological and Chemical Discovery (ABCD): Centralizing Discovery Knowledge in an Inherently Decentralized World , 2007, J. Chem. Inf. Model..
[28] Alexander Chuprina,et al. Drug- and Lead-likeness, Target Class, and Molecular Diversity Analysis of 7.9 Million Commercially Available Organic Compounds Provided by 29 Suppliers , 2010, J. Chem. Inf. Model..
[29] Jörg Rademann,et al. Design of chemical libraries with potentially bioactive molecules applying a maximum common substructure concept , 2009, Molecular Diversity.
[30] Carol A. Mulrooney,et al. Build/couple/pair strategy for the synthesis of stereochemically diverse macrolactams via head-to-tail cyclization. , 2012, ACS combinatorial science.
[31] Peter S. Kutchukian,et al. Rethinking molecular similarity: comparing compounds on the basis of biological activity. , 2012, ACS chemical biology.
[32] Stuart L. Schreiber,et al. Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles , 2010, Proceedings of the National Academy of Sciences.
[33] Thomas Sander,et al. OSIRIS, an Entirely in-House Developed Drug Discovery Informatics System , 2009, J. Chem. Inf. Model..